✨ Your Portfolio is fetched and updated from zerodha.
Pharmaceuticals
Market Cap
₹0 Cr.
P/E
0.00

Key Ratios

Market cap
Market cap
-
PE
PE
-
Prom Holding
Prom Holding
-
ROE (%)
ROE (%)
24.65
ROCE (%)
ROCE (%)
30.24
Div Yield (%)
Div Yield (%)
-
Sales
Sales
1,196 Cr
OPM (%)
OPM (%)
2.01 %
Debt to Equity
Debt to Equity
0.10

About

CORONA Remedies Ltd. develops, manufactures, and markets prescription and OTC medicines across… Read more
Low
52W Range
High

Insufficient data

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

0 Yes

Positive for this company

0 Neutral

Neutral for this company

0 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Location Wise Break-Up

Therapeutic Area Break-Up

Acute vs Chronic

Asset Break-Up - Geography Wise

Operational Metrics

    Select a Metric

    Peer Comparison

    FAQs on CORONA Remedies Ltd. Business

    Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product portfolio comprises brands that cater to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory.

    CORONA Remedies major competitors are Abbott India, Alkem Laboratories, Eris Lifesciences, Glaxosmithkline Phar, JB Chem & Pharma, Mankind Pharma, Pfizer.
    Market Cap of CORONA Remedies is ₹0 Crs.
    While the median market cap of its peers are ₹28,413 Crs.

    CORONA Remedies seems to be less financially stable compared to its competitors.
    Altman Z score of CORONA Remedies is 0 and is ranked 7 out of its 8 competitors.

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material